Neuronetrix has been selected by Anavex Life Sciences Corp. to support the upcoming Phase 2a clinical trial for ANAVEX 2-73
LOUISVILLE, Ky., Nov. 7, 2014 /PRNewswire/ -- Neuronetrix has been selected by Anavex Life Sciences Corp. (OTCQB: AVXL) to support the upcoming Phase 2a clinical trial for ANAVEX 2-73, a symptomatic and potentially disease-modifying treatment for Alzheimer's disease. Neuronetrix will be utilizing their COGNISION™ System to measure and analyze cognitive biomarkers in study participants.
The ANAVEX 2-73 study incorporates an adaptive design, with an enrollment of 32 mild to moderate Alzheimer's disease patients. Key performance measures will be collected over 6 months, at up to seven (7) sites in Australia.
COGNISION™ is an easy to use, reliable system that provides physiological measures of cognitive processing ("cognitive biomarkers"). These biomarkers are particularly important in pharmaceutical development of pro-cognitive therapeutics by providing sensitive measures of targeted drug effects.
"Due to COGNISION™'s cloud based structure, our systems are specifically designed to be used in multi-site clinical trials that require immediate data analysis. We are excited to be a part of this important treatment study," said Dr. Marco Cecchi, Neuronetrix's Director of Research and Clinical Affairs.
Dr. Christopher U. Missling, President and Chief Executive Officer of Anavex added, "Their expertise, reputation, and experience supporting clinical studies were all factors that influenced our decision to select Neuronetrix and their COGNISION™ Systems."
About COGNISION™
The COGNISION™ System is a proprietary neuro-electrophysiological device which provides objective assessments of cognitive function. COGNISION™ implements powerful and validated scientific methods in a practical, cost effective, and easy to use design.
About Neuronetrix
Neuronetrix, developer of the COGNISION™ System, is a leading neurotech company focused on providing physicians and scientists with accurate and meaningful information about brain processing. This information is critical in the understanding of complex brain function, diagnosis of cognitive disorders, and evaluating the effects of pro-cognitive therapies.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (OTCQB: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug candidates to treat Alzheimer's disease, other Central Nervous System (CNS) diseases, and various types of cancer. Anavex's lead drug candidates, ANAVEX 2-73 and ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept®), are currently in a Phase 2a clinical trial for Alzheimer's disease. ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean data profile. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. The drug combination ANAVEX PLUS produced up to 80% greater reversal of memory loss in Alzheimer's disease models versus when the drugs were used individually. Further information is available at www.anavex.com.
Additional information about Neuronetrix is available at http://www.neuronetrix.com or by contacting Daniel Lawson at [email protected], or (502) 561-9040, x7003.
Additional information about Anavex Life Sciences Corp. is available at http://www.anavex.com, toll-free (844)-689-3939, or email [email protected].
SOURCE Neuronetrix
Share this article